2023-09-28T05:04:58+03:00[Europe/Moscow] en true <p>age &lt; 5, elderly </p>, <p>ICS+form, airsupra, SABAs, SAMA, systemic corticosteroids, inhaled epinephrine</p>, <p>albuterol + budesonide </p>, <p>SABAs</p>, <p>d</p>, <p>d</p>, <p>b</p>, <p># of days of use, symptom frequency </p>, <p>c</p>, <p>ipratropium + albuterol nebulizer </p>, <p>a</p>, <p>speed recovery, prevent recurrence, increase response to SABA, decrease hospital admissions</p>, <p>4-12 hours </p>, <p>f; oral is preferred </p>, <p>until PEF 80% of predicted/personal best</p>, <p>e</p>, <p>e</p>, <p>mild; intermittent </p>, <p>potent; effective</p>, <p>2x daily </p>, <p>low-medium</p>, <p>smokers, neutrophilic inflammation, AA children </p>, <p>rinse mouth w/water; can use space/VHC w non-breath activated MDI, administer less frequently </p>, <p>formoterol </p>, <p>urinary retention; glaucoma </p>, <p>f; LAMA + ICS has no effect on exacerbations </p>, <p>2-6 weeks </p>, <p>1-6</p>, <p>3 months </p>, <p>assess asthma severity prior to starting treatment; assess asthma control after therapy for monitoring/adjusting </p>, <p>symptoms, use of SABAs, limitations to normal activities, pulmonary function, exacerbations</p>, <p>c</p>, <p>c</p>, <p>a</p>, <p>b</p>, <p>b</p>, <p>c</p>, <p>assess severity &amp; control, education, control environmental/comorbidities, medication </p> flashcards
Asthma therapeutics

Asthma therapeutics

  • age < 5, elderly

    Who should we avoid using DPIs in ? (2)

  • ICS+form, airsupra, SABAs, SAMA, systemic corticosteroids, inhaled epinephrine

    What are the quick relief medications (6)?

  • albuterol + budesonide

    Airsupra =

  • SABAs

    Chronic use is NOT recommended with __________.

  • d

    Which is LABA w/ fast onset?

    a) systemic corticosteroids

    b) SABAs

    c) SAMAs

    d) ICS + formoterol

    e) inhaled epinephrine

  • d

    Which is used intermittently/prn ?

    a) systemic corticosteroids

    b) SABAs

    c) SAMAs

    d) ICS + formoterol

    e) inhaled epinephrine

  • b

    According to the NHLBI, ______ is the DOC for acute symptoms.

    a) systemic corticosteroids

    b) SABAs

    c) SAMAs

    d) ICS + formoterol

    e) inhaled epinephrine

  • # of days of use, symptom frequency

    What are the key monitoring points for SABAs? (2)

  • c

    Which is an additive that can ONLY be used in ER setting?

    a) systemic corticosteroids

    b) SABAs

    c) SAMAs

    d) ICS + formoterol

    e) inhaled epinephrine

  • ipratropium + albuterol nebulizer

    Combivent =

  • a

    Which is used in non-responsive asthma?

    a) systemic corticosteroids

    b) SABAs

    c) LAMAs

    d) ICS + formoterol

    e) inhaled epinephrine

  • speed recovery, prevent recurrence, increase response to SABA, decrease hospital admissions

    What are systemic corticosteroids used for clinically? (4)

  • 4-12 hours

    How long does it take to see a clinical response from systemic

    corticosteroids?

  • f; oral is preferred

    IV route is preferred in systemic corticosteroid use. T/F?

  • until PEF 80% of predicted/personal best

    How long do we continue systemic steroid use?

  • e

    Which is available OTC?

    a) systemic corticosteroids

    b) SABAs

    c) LAMAs

    d) ICS + formoterol

    e) inhaled epinephrine

  • e

    Which is NOT included in asthma guidelines?

    a) systemic corticosteroids

    b) SABAs

    c) LAMAs

    d) ICS + formoterol

    e) inhaled epinephrine

  • mild; intermittent

    Inhaled epinephrine is FDA approved for _______ symptoms in _________ asthma only.

  • potent; effective

    Inhaled corticosteroids (ICS) are the most _____ & ______ medications

    available for asthma.

  • 2x daily

    How often do patients with moderate asthma need to take their ICS?

  • low-medium

    What kind of ICS dose is used for patients with moderate asthma?

  • smokers, neutrophilic inflammation, AA children

    Corticosteroid responsiveness may be decreased in what patients (3)

  • rinse mouth w/water; can use space/VHC w non-breath activated MDI, administer less frequently

    How can we prevent AE's w ICS?

  • formoterol

    What is our MART (Maintenance and Reliever Therapy)?

  • urinary retention; glaucoma

    Patients with what conditions should NOT receive LAMA therapy? (2)

  • f; LAMA + ICS has no effect on exacerbations

    In adults with uncontrolled persistent asthma, LAMA + ICS is just as effective

    as LABA + ICS. T/F?

  • 2-6 weeks

    When is the initial follow up?

  • 1-6

    Once controlled, visits can be in ________ month intervals.

  • 3 months

    How long does a patient need to be controlled in order to step down their therapy?

  • assess asthma severity prior to starting treatment; assess asthma control after therapy for monitoring/adjusting

    What are the goals of clinical management? (2)

  • symptoms, use of SABAs, limitations to normal activities, pulmonary function, exacerbations

    How is severity & control measured? (5)

  • c

    Intrinsic intensity of the disease process.

    a) responsiveness

    b) control

    c) severity

  • c

    Easiest to measure when patient is NOT receiving long-term control therapy.

    a) responsiveness

    b) control

    c) severity

  • a

    The ease with which asthma control is achieved by therapy.

    a) responsiveness

    b) control

    c) severity

  • b

    The degree to which manifestations are minimized by therapeutic

    intervention & goals of therapy are met.

    a) responsiveness

    b) control

    c) severity

  • b

    Assess ____ to adjust therapy.

    a) responsiveness

    b) control

    c) severity

  • c

    Assess ____ to initiate therapy.

    a) responsiveness

    b) control

    c) severity

  • assess severity & control, education, control environmental/comorbidities, medication

    What are the 4 components of asthma care?